No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include microbial pharmaceutical raw materials, biological pesticides, fertilizers, biochemical nutritional products, and preventive medicines. The company further manufactures dietary supplements and provides comprehensive contract manufacturing services for supplements, accommodating various formats such as sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies. Syngen Biotech also develops and markets science-backed bioactive pharmaceutical ingredients (APIs) under proprietary brands including Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL. Additional services encompass private labelling, organic food OEM/ODM, explosion-proof extraction, brand agency, and wholesale distribution. Syngen Biotech caters to numerous industries, such as sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox. The company actively exports its products to approximately 20 countries worldwide.

• Island Pharmaceuticals Limited
• Acrivon Therapeutics, Inc. Common Stock
• Adicet Bio, Inc.
• Kalaris Therapeutics Inc
• Champions Oncology, Inc.
• Equillium, Inc.
• OS Therapies Incorporated
• SUSMED,Inc.